New appointments at Varian

Varian has appointed Kolleen T. Kennedy, formerly president of Varian Oncology Systems (VOS) to a new role as president of Proton Solutions, the division formerly known as Particle Therapy, and chief growth officer. Chris Toth, formerly president of Global Commercial and Field Operations, will succeed Kennedy as the new president of VOS. Both executives will report directly to Dow Wilson, Varian’s president and chief executive officer and both changes are effective immediately.

Kennedy most recently served as president of VOS where she was responsible for running the company’s most profitable operating group, comprising more than 5000 employees worldwide. In her new role, Kennedy will be responsible for growing Varian Proton Solution’s offerings as well as overseeing the company’s acquisition integration office, strategic program management organization, and customer experience initiatives.

Toth has held many cross-functional roles during his tenure and was most recently president, Global Commercial and Field Operations, where he was responsible for global sales strategy and execution for both VOS and Varian Proton Solutions.